Celcuity (NASDAQ:CELC - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.
Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.13). On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Celcuity Price Performance
CELC stock traded down $0.38 during midday trading on Friday, reaching $10.15. The company had a trading volume of 141,339 shares, compared to its average volume of 299,856. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity has a 1 year low of $7.58 and a 1 year high of $19.77. The company has a market capitalization of $384.07 million, a P/E ratio of -3.89 and a beta of 0.56. The firm has a 50-day moving average price of $10.11 and a 200-day moving average price of $11.82.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research note on Friday, April 11th. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Celcuity in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $30.17.
Check Out Our Latest Report on Celcuity
Celcuity Company Profile
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Further Reading
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
